Dyne Therapeutics Inc. Common Stock
(NASDAQ:DYN)
Description
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was founded in 2017 and is headquartered in Waltham, Massachusetts.
DYN Overview
None
Sector |
Health Care |
Industry |
Major Pharmaceuticals |
Previous Close |
$11.1000 |
Previous Close Volume |
369460 |
Latest News
-
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
28 May 2024 13:03:02
https://investors.dyne-tx.com/news-and-events/press-releases/